Abstract
Pancreatic ductal adenocarcinoma (PDAC) is more prevalent in older patients, but early-onset cases (<55 years) may be a distinct genetic subpopulation. Differential expression of CDKN2A and transcription factor FOXC2 were found in early-onset cases. This finding opens the door to investigating additional features that distinguish PDAC tumors in this age group.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 8-10 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 27 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2021 |
Bibliographical note
Funding Information:E. Lou reports research grants from the American Association for Cancer Research (2019 AACR-Novocure Tumor-Treating Fields Research Grant) and the Minnesota Ovarian Cancer Alliance; honorarium and travel expenses for a research talk at GlaxoSmithKline (2016); honoraria and travel expenses for lab-based research talks, and equipment for laboratory-based research from Novocure (2018–20); consultant, Nomocan Pharmaceuticals (unpaid); scientific advisory board member, Minnetronix, LLC (2018–present; unpaid); consultant and speaker honorarium, Boston Scientific US (2019); institutional principal investigator for clinical trials sponsored by Celgene, Novocure, Intima Biosciences, and the NCI; and University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (unpaid).
Publisher Copyright:
© 2020 American Association for Cancer Research.
